A total of 27 patients with NSCLC who received ICIs, as well as EGFR‐TKIs, which were treated more than one compound, between February 2016 and April 2018 at 6 institutions in Japan were included. This evidence concerns the gene EGFR and non-small cell lung carcinoma.